



Urovant Sciences Appoints James Robinson to its Board of Directors

March 6, 2019

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Mar. 6, 2019-- Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today announced James Robinson, President and Chief Operating Officer of Alkermes, will join its Board of Directors.

This press release features multimedia. View the full release here: <https://www.businesswire.com/news/home/20190306005182/en/>



“Jim’s extensive leadership, knowledge and experience in the biopharmaceutical space combined with his unique understanding of the urology market will help inform Urovant’s strategies and growth opportunities,” said Keith A. Katkin, Chief Executive Officer of Urovant. “Urovant is pleased to welcome him to our board and my team and I are looking forward to his counsel and contributions.”

“Jim has demonstrated unwavering leadership in the competitive and complex biopharmaceutical market,” said Myrtle Potter, Chairman of the Urovant Sciences Board. “Given the trajectory of Urovant, Jim’s extensive commercial experience will certainly benefit Urovant and its management team.”

Mr. Robinson has more than 27 years of commercial and operations experience in the biopharmaceutical industry, specifically in the urology, oncology, cardiovascular, infectious disease, hepatitis and CNS markets. Since March 2018, he has held the position of President and Chief Operating Officer at Alkermes, where he is responsible for the global commercial, new product planning, corporate planning, manufacturing, quality, human resource and business development functions. Prior to Alkermes, Mr. Robinson spent over 13 years at Astellas US – most recently as President, Americas Operations, from April 2016 through February 2018, where his responsibilities included all aspects of commercial, corporate development, human resources, finance, corporate affairs, compliance, legal and international

Urovant Sciences Appoints James Robinson to its Board of Directors (Photo: Business Wire)

operations for North and South America. Prior to his role as President of Americas Operations, Mr. Robinson was President, Astellas Pharma US, from April 2013 through March 2016, where he was responsible for leading the US commercial organization. Prior to Astellas, Mr. Robinson spent 13 years at Schering-Plough Pharmaceuticals where his last role was Vice President, Hepatitis Sales and Managed Care.

“I am pleased to join Urovant’s board and work with a company that is passionate about developing and commercializing innovative products to address the needs of urology patients who oftentimes suffer in silence,” said Mr. Robinson. “I look forward to working with Keith and his leadership team.”

Mr. Robinson serves on the Board of Directors for Neos Therapeutics. He is a founding member and serves on the Board of Directors of MATTER and is also on the Board of Directors for the Chicago Botanic Garden. He received his Bachelor of Science degree from DePaul University.

About Urovant Sciences

Urovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions. Urovant’s lead product candidate, vibegron, is an oral, once-daily, small molecule beta-3 agonist being evaluated for the treatment of OAB with symptoms of urge urinary incontinence, urgency, and urinary frequency; for OAB in men with benign prostatic hyperplasia; and for abdominal pain associated with irritable bowel syndrome. Urovant has licensed global rights, excluding Japan and certain Asian territories, for the development and

commercialization of vibegron. Urovant's second product candidate, URO-902, is a novel gene therapy being developed for patients with OAB who have failed oral pharmacological therapy. Urovant intends to develop treatments for additional urologic diseases. For more information, please visit www.urovant.com.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190306005182/en/>

Source: Urovant Sciences

Investor inquiries: Investors@Urovant.com

Media inquiries: Media@Urovant.com